Home / Psoriasis / Insulin Sensitivity, Glucose – and Fat Metabolism in Patients With Psoriasis

Insulin Sensitivity, Glucose – and Fat Metabolism in Patients With Psoriasis

  Purpose

The pathophysiological mechanisms explaining the association between psoriasis and type 2 diabetes are largely unknown but it has been hypothesized that systemic inflammation found in both psoriasis and type 2 diabetes might play a role. In a recent study hyperinsulinaemic euglycaemic clamps were performed and it showed that normal glucose-tolerant patients with moderate to severe psoriasis had lower whole-body insulin sensitivity during insulin stimulation compared to healthy matched controls. Thus, the increased risk of type 2 diabetes in patients with psoriasis appears to include defects in the glucose metabolism linked to psoriasis itself. However, the methods applied did not allow a detailed characterization of the metabolism in patients with psoriasis. Tracer technique combined with indirect calorimetry has never been applied to study hepatic and whole body insulin sensitivity, and glucose and fat oxidation, during basal conditions or during insulin stimulation in patients with psoriasis.

Aim of study:

The aim of this study is to investigate hepatic and whole body insulin sensitivity and glucose and fat oxidation during both basal and insulin-stimulated conditions in patients with psoriasis.

Condition Intervention
Insulin Sensitivity Metabolism Disorder Other: Stabile Isotope tracers

Study Type: Observational
Study Design:Observational Model: Case-Control
Time Perspective: Prospective
Official Title:Insulin Sensitivity, Glucose – and Fat Metabolism in Patients With Psoriasis

Resource links provided by NLM:

Further study details as provided by Filip Krag Knop, University Hospital, Gentofte, Copenhagen:

Primary Outcome Measures:

  • Insulin sensitivity [ Time Frame: 6 hours ]
    Experimental day 2

Secondary Outcome Measures:

  • Non-oxidative glucose metabolism [ Time Frame: 6 hours ]
    Experimental day 2

  • Endogenous glucose production [ Time Frame: 6 hours ]
    Experimental day 2

  • Lipolysis [ Time Frame: 6 hours ]
    Experimental day 2

  • glucose oxidation [ Time Frame: 6 hours ]
    Experimental day 2

  • Fat oxidation [ Time Frame: 6 hours ]
    Experimental day 2

  • Molecular changes in muscle and fat tissue [ Time Frame: 6 hours ]
    Experimental day 2

  • Beta-cell secretion rate [ Time Frame: 1 hour ]
    Experimental day 1

Biospecimen Retention:   Samples With DNA

Muscle and fat biopsies. Blood samples.

Estimated Enrollment:32
Study Start Date:August 2016
Estimated Study Completion Date:August 2018
Estimated Primary Completion Date:August 2018 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Patients with Psoriasis

Patients with moderate to severe psoriasis (PASI>8)
Other: Stabile Isotope tracers

Non-radioactive tracers used in hyperinsulinaemic euglycaemic clamp
Other Name: [6,6-D2]glucose, [1,1,2,3,3,-D5]glycerol
Healthy Control Subjects

Healthy subjects matching the patients with psoriasis regarding age, gender and BMI
Other: Stabile Isotope tracers

Non-radioactive tracers used in hyperinsulinaemic euglycaemic clamp
Other Name: [6,6-D2]glucose, [1,1,2,3,3,-D5]glycerol

  Show Detailed Description

About

Check Also

Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation (IMMPRESS)

Study Description Go to  Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Brief Summary: The purpose of this study is to assess the safety and efficacy of risankizumab compared to placebo in subjects with moderate to severe chronic plaque psoriasis in the Russian Federation. Condition …

Leave a Reply

Your email address will not be published. Required fields are marked *